View More Recent Stories

Mar 14, 2025 09:11AM Stifel Reiterates Buy Rating on Regenxbio Inc. (RGNX)
Mar 13, 2025 04:13PM Regenxbio (RGNX) Tops Q4 EPS by 12c
Mar 4, 2025 07:31AM Regenxbio (RGNX) Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases
Feb 11, 2025 03:58AM Goldman Sachs Downgrades Regenxbio Inc. (RGNX) to Neutral
Feb 6, 2025 04:02PM Raymond James Starts Regenxbio Inc. (RGNX) at Outperform
Jan 15, 2025 06:41AM H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX)
Jan 14, 2025 06:09AM Regenxbio (RGNX) and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111
Jan 13, 2025 08:31AM AbbVie (ABBV) and REGENXBIO (RGNX) Announce Updates on the ABBV-RGX-314 Clinical Program
Dec 6, 2024 07:40PM Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
Dec 6, 2024 05:27PM Apollo Global Management (APO) and Workday (WDAY) to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
Nov 21, 2024 06:36AM Regenxbio Inc. (RGNX) PT Lowered to $36 at H.C. Wainwright
Nov 18, 2024 02:15PM Raymond James Reiterates Outperform Rating on Regenxbio Inc. (RGNX)
Nov 18, 2024 07:10AM Regenxbio (RGNX) Initiates Pivotal Phase Of Affinity Duchenne® Trial Of Rgx-202 Gene Therapy And Reports Positive Functional Data
Nov 15, 2024 03:19AM Morgan Stanley Assumes Regenxbio Inc. (RGNX) at Overweight
Nov 6, 2024 05:00PM Regenxbio (RGNX) Misses Q3 EPS by 5c
Oct 21, 2024 07:06AM Regenxbio (RGNX) Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024
Oct 10, 2024 08:22AM Raymond James Resumes Regenxbio Inc. (RGNX) at Outperform
Sep 17, 2024 07:07AM Regenxbio (RGNX) Appoints Mitchell Chan as CFO
Sep 5, 2024 06:48AM H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX)
Sep 3, 2024 08:05AM Regenxbio (RGNX) Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect
Aug 1, 2024 04:41PM Regenxbio (RGNX) Tops Q2 EPS by 24c, provides guidance
Aug 1, 2024 07:03AM Regenxbio (RGNX) Announces New Positive Data From Affinity Duchenne® Trial Of Rgx-202
Jul 19, 2024 06:38AM RBC Capital Reiterates Outperform Rating on Regenxbio Inc. (RGNX)
Jun 24, 2024 02:13PM Stifel Reiterates Buy Rating on Regenxbio Inc. (RGNX)
Jun 24, 2024 07:05AM Regenxbio (RGNX) Announces Expansion of AFFINITY DUCHENNE Trial
Jun 21, 2024 06:35AM H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX)
Jun 20, 2024 07:23AM RBC Capital Reiterates Outperform Rating on Regenxbio Inc. (RGNX)
Jun 18, 2024 07:06AM Regenxbio (RGNX) Announces Successful Pre-BLA Meeting with FDA
Jun 12, 2024 07:05AM Regenxbio (RGNX) Appoints Curran Simpson as CEO
View More Recent Stories